Everest Medicines   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2012)

Organization Overview

First Clinical Trial
2020
NCT04699643
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

EVEREST LIFE SCI | Everest Medicines | Everest Medicines (China) Co.,Ltd. | Everest Medicines (Singapore) Pte. Ltd. | EverNov Medicines (Zhuhai Hengqin) Co., Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 11